Clinical pharmacokinetics of intranasal sumatriptan.

@article{Fuseau2002ClinicalPO,
  title={Clinical pharmacokinetics of intranasal sumatriptan.},
  author={Eliane Fuseau and Olivier Petricoul and Katy H. P. Moore and Andrew Barrow and Tim Ibbotson},
  journal={Clinical pharmacokinetics},
  year={2002},
  volume={41 11},
  pages={801-11}
}
A substantial proportion of migraine patients have gastric stasis and suffer severe nausea and/or vomiting during their migraine attack. This may lead to erratic absorption from the gastrointestinal tract and make oral treatment unsatisfactory. For such patients, an intranasal formulation may be advantageous. Sumatriptan is a potent serotonin 5HT(1B/1D) agonist widely used in the treatment of migraine; the effectiveness of the intranasal formulation (20mg) has been well established in several… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…